Medtronic Plc

WASHINGTON, March 7, 2026 /PRNewswire/ -- Today at the Cardiovascular Research Technologies (CRT) annual conference taking place in Washington, DC, Dr. Christopher Chieh Yang Koo from National University Hospital Singapore, on behalf of investigators from Smith Center for Outcomes Research in Cardiology at Harvard Medical School, presented the first-ever US Medicare outcomes data for angiography-derived physiology (ADP) in a Late-Breaking Clinical Trial (LBCT) that was simultaneously published in Circulation: Cardiovascular Interventions. This study highlights the rapidly growing adoption of CathWorks FFRangio in the United States while demonstrating similar clinical outcomes as invasive pressure wire-guided PCI through 2 years. Continue Reading Late-Breaking Clinical Trial Presentation of the First-Ever US Cohort of Over 4,000 CathWorks FFRangio Patients Demonstrates Similar Clinical Outcomes to Invasive Pressure Wire-Guided PCI through Two Years The Medicare data from 2019 to 2024 were used to identify inpatient and outpatient physiological assessments performed with ADP or invasive pressure wire. ADP was propensity matched 1:3 to invasive pressure wire in patients who underwent PCI and separately in those who did not undergo PCI. The primary outcome was the cumulative incidence of major adverse cardiac events (MACE) through 2 years (death, myocardial infarction (MI) or repeat revascularization). Secondary outcomes included each component of MACE, 30-day acute kidney injury and major bleeding. Cost ratios for repeat revascularization and hospital readmissions through 1 year were calculated. Among 466,535 invasive physiology assessments, ADP utilization grew nearly 8-fold between 2019 and 2024. In the PCI group, 1,591 ADP and 4,773 invasive pressure wire matched patients, the cumulative incidence of MACE was comparable through 2 years (24.8% vs. 23.5%; HR 1.01, 95% CI 0.85-1.20). In the non-PCI group, 2,532 ADP and 7,596 invasive pressure wire matched patients also had comparable MACE through 2 years (24.1% vs. 23.9%; HR 0.97, 95% CI 0.84-1.11). "This first look at contemporary data of the growing adoption of ADP in the United States shows similar clinical outcomes including death, MI and revascularization through 2 years when compared with invasive pressure wires. When considering the promising secondary outcomes such as resource utilization advantages and the growing clinical body of evidence, specifically for CathWorks FFRangio, we expect the current trend of adoption for ADP to continue to grow at an even faster rate," said Dr. Eric A. Secemsky, Director of Vascular Intervention at Beth Israel Deaconess Medical Center. "This large US cohort adds to the strategically planned robust body of clinical evidence for CathWorks FFRangio. Considering these data were predominantly based on an earlier generation of CathWorks FFRangio and taking into account the commercial adoption over the last few years, we are very encouraged that the latest innovations within the CathWorks platform further streamline its integration within the clinical workflow while still providing similar outcomes. CathWorks FFRangio is well positioned to become the new standard of care for physiology, but all ADP technologies are not created equally and do not yield similar outcomes. Each technology should be evaluated based on its own peer-reviewed clinical evidence," said Ramin Mousavi, CathWorks President & CEO. Read the simultaneously published study: ABOUT CATHWORKS CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit and follow @CathWorks on LinkedIn. Investors: Mike Feher [email protected] Media: Sarita Monico [email protected] SOURCE CathWorks 21% more press release views with Request a Demo

GALWAY, Ireland, March 6, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that MiniMed Group, Inc. (Nasdaq: MMED) will begin trading today on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol "MMED" in connection with its initial public offering ("IPO"). "Today marks an exciting milestone for both MiniMed and Medtronic. Despite a challenging market backdrop shaped by geopolitical uncertainty, the teams successfully executed an oversubscribed offering and the second largest IPO in Medtech history," said Geoff Martha, Medtronic chairman and chief executive officer. "Establishing MiniMed as a standalone entity positions the company to operate with greater agility over the long term. At the same time, this transaction supports Medtronic's strategy to focus capital and resources on long term value creation opportunities that leverage our scale, synergies, and core competencies. We congratulate Que Dallara and our Diabetes colleagues whose leadership and dedication made this moment possible." About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit and follow Medtronic on LinkedIn. Medtronic Contacts Justin Paquette Public Relations +1-612-271-7935 Ingrid Goldberg Investor Relations +1-763-505-2696 SOURCE Medtronic plc 21% more press release views with Request a Demo

Medtronic and GE HealthCare inked a multiyear deal to expand their more than three-decade-long partnership that aims to boost clinical and technology innovation.\n Medtronic and GE HealthCare inked a multiyear deal to expand their more than three-decade- long partnership that aims to boost clinical and technology innovation.GE HealthCare is looking to adopt Medtronic’s next-generation technologies into its patient care platforms, including expanding its offering into wireless wearable solutions and anesthesia airway visualization, they said in a March 3 press release.Financial details of the collaboration weren’t disclosed.“Expanding access to our combined technologies and commercial solutions allows hospitals to streamline their operations, reduce inefficiencies, and ultimately empower clinicians to focus on what matters most: their patients,” Kate Benedict, president of Medtronic’s acute care and monitoring business, said in a statement. As part of the collaboration, Medtronic will integrate its technology (Nellcor pulse oximetry, Microstream capnography, Invos regional oximetry and BIS brain monitoring) into GE HealthCare’s monitoring platforms.Medtronic and GE HealthCare also committed to expanding the adoption and use of Nellcor and BIS across multiple platforms for improved patient care.In late February, Medtronic announced it was looking to raise $784 million in a public offering of its MiniMed diabetes division.The spinout was announced last year, is part of Medtronic’s move to simplify its portfolio and is expected to be completed by the end of 2026.